Accendra Health, Inc.
NYSE:ACHMedical - Distribution
+$0.12 today
- Market cap
- $54.22M
- Beta
- 1.63
- P/E (TTM)
- -0.2
- EPS (TTM)
- -$14.11
Volume 1.41M
Average 0.83M
ACH Net Margin
Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.
Accendra Health, Inc.NYSE: ACH
Net Margin · Q1 FY2026 · quarter ended Mar 2026
Net margin holds steady near -1.0%
Net margin was -1.0% in Q1 FY2026, down 0.1 pp from a year earlier. On a trailing-twelve-month basis it was -39.8%, down 34.4 pp year over year. Over 3 fiscal years it narrowed by 40.1 pp.
Context
- Net margin widened in 0 of the last 3 fiscal years.
- FY2025 was the lowest level in the 4 fiscal years shown.
What to watch
Whether net margin reaches the consensus estimate from 4 analysts of 0.0% for the fiscal year ending Dec 2026, up from -39.8% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -1.0%+6.9 pp QoQ
- Last fiscal yearDec 2025
- -39.8%-36.5 pp YoY
- LTMMar 2026
- -39.8%-34.4 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -0.1 pp | +126.4 pp | +126.5 pp |
| 1 year | -36.5 pp | +39.9 pp | +76.4 pp |
| 3 years | -40.1 pp | +40.8 pp | +80.9 pp |
| 5 years | +42.0 pp | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -39.8%
- Year-over-year change
- -36.5pp
| Period | Period end | Net Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -39.8% | -36.5pp |
| FY2024 | 2024-12-31 | -3.4% | -3.0pp |
| FY2023 | 2023-12-31 | -0.4% | -0.6pp |
| FY2022 | 2022-12-31 | 0.2% | -2.0pp |
| FY2021 | 2021-12-31 | 2.3% | — |
Net Margin vs competitors
How ACH compares with its peers on the latest reported figures
- ACH's LTM Mar 2026 net margin of -39.8% is the 2nd highest of the 9 companies compared; the peer median is -103.3%.
- Its year-over-year change of -34.4 pp is the 8th highest of 9, against a peer median of +25.7 pp.
- Over three fiscal years its change of -40.1 pp compares with a peer median of +72.9 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Apr 2026 | -6.6% | -4.8 pp | +11.6 pp | |
| LTM Mar 2026 | -39.8% | -34.4 pp | -40.1 pp | |
| LTM Mar 2026 | -46.8% | +16.4 pp | +71.2 pp | |
| LTM Mar 2026 | -63.7% | +35.1 pp | +72.9 pp | |
| LTM Mar 2026 | -89.1% | +8.3 pp | +90.3 pp | |
| LTM Mar 2026 | -117.4% | +105.0 pp | +907.9 pp | |
| LTM Mar 2026 | -281.6% | +419.5 pp | +723.2 pp | |
| LTM Mar 2026 | -832.6% | -100.2 pp | -537.5 pp | |
BIOABioAge Labs, Inc. | LTM Mar 2026 | -871.8% | +4024.5 pp | — |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| Peer median (excluding ACH) | -103.3% | +25.7 pp | +72.9 pp | |
Competitors are the stored peer set for ACH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 9.79B | 9.96B | 10.33B | 10.7B | 2.76B |
| Cost of Revenue | 8.27B | 8.13B | 8.21B | 8.48B | 1.56B |
| Gross Profit | 1.51B | 1.83B | 2.13B | 2.22B | 1.2B |
| Gross Margin | 15.5% | 18.3% | 20.6% | 20.7% | 43.5% |
| Research & Development | 12.1M | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 1.08B | 1.55B | 1.81B | 1.91B | 1.05B |
| Operating Expenses | 1.14B | 1.68B | 2.02B | 2.43B | 1.05B |
| Depreciation & Amortization | 90.62M | 228.67M | 287.38M | 264.78M | 214.52M |
| EBITDA | 415.47M | 368.45M | 390.57M | 51.22M | 364.68M |
| EBITDA Margin | 4.2% | 3.7% | 3.8% | 0.5% | 13.2% |
| Operating Income | 368.47M | 142.91M | 104.51M | (207.77M) | 150.16M |
| Operating Margin | 3.8% | 1.4% | 1.0% | -1.9% | 5.4% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 48.09M | 128.89M | 157.92M | 143.8M | 129.2M |
| Other Income / Expenses | (91.72M) | (132.02M) | (159.23M) | (149.59M) | (252.11M) |
| Income Before Tax | 276.75M | 10.89M | (54.73M) | (357.36M) | (101.95M) |
| Pre-Tax Margin | 2.8% | 0.1% | -0.5% | -3.3% | -3.7% |
| Income Tax Expense | 55.17M | (11.5M) | (13.43M) | 5.33M | 729K |
| Net Income | 221.59M | 22.39M | (41.3M) | (362.69M) | (1.1B) |
| Net Margin | 2.3% | 0.2% | -0.4% | -3.4% | -39.8% |
| EPS (Basic) | 3.05 | 0.30 | (0.54) | (4.73) | (14.31) |
| EPS (Diluted) | 2.94 | 0.29 | (0.54) | (4.73) | (14.31) |
| Weighted Avg Shares | 72.74M | 74.5M | 75.79M | 76.74M | 76.9M |
| Weighted Avg Shares (Diluted) | 75.49M | 76.22M | 75.79M | 76.74M | 76.9M |
Accendra Health, Inc.
NYSE:ACH
Intrinsic Alpha fair value
Locked
Current Price
$0.71
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.